BioCentury | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

...College London ; Oxford Biomedica plc (LSE:OXB); University of Oxford ; University of Edinburgh ; Imperial Innovations...
BioCentury | Aug 10, 2018
Company News

Boehringer, U.K. groups partner for CF gene therapy

...to develop a gene therapy to treat cystic fibrosis. Partners include Oxford BioMedica plc (LSE:OXB), Imperial Innovations...
...Financial terms were undisclosed. Boehringer Ingelheim GmbH, Ingelheim, Germany Oxford BioMedica plc (LSE:OXB), Oxford, U.K. Imperial Innovations...
...Oxford, Oxford, U.K. University of Edinburgh, Edinburgh, U.K. Business: Pulmonary Michael von Emster Boehringer Ingelheim GmbH Imperial College London Imperial Innovations...
BioCentury | Jun 11, 2018
Company News

Management tracks: Arbutus, Cancer Research UK

...U.K.) hired Tony Hickson as CBO, effective in August. He is managing director at the Imperial Innovations...
BioCentury | Apr 30, 2018
Financial News

Andera leads Crescendo’s $70M series B

...a timeline. The company raised $28.6 million in a 2013 series A round led by Imperial Innovations...
BioCentury | Oct 26, 2017
Strategy

Capital call

...But there’s an interesting model seen with BTG plc , IP Group plc , and Imperial Innovations...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...2016 with £40 million ($57 million) by UCL, Cambridge University and Imperial College London ’s Imperial Innovations...
BioCentury | Mar 25, 2017
Finance

Respiratory redux

...an undisclosed sum. Pulmocide also has three investors in common with RespiVert: SV Life Sciences, Imperial Innovations...
BioCentury | Nov 11, 2016
Financial News

Enterprise Therapeutics completes venture financing

...£4 million ($5 million) in a venture round led by existing investors Epidarex Capital and Imperial Innovations...
BioCentury | Nov 11, 2016
Emerging Company Profile

Golden opportunity

...partners: None Number of employees: 14 Funds raised: £7 million ($8.6 million) Investors: Brandon Capital, Imperial Innovations...
BioCentury | Oct 3, 2016
Financial News

Artios completes venture financing

...2016-09-21 Type: Venture financing Raised: $33.2 million Investors: SV Life Sciences ; Merck Ventures B.V.; Imperial Innovations...
Items per page:
1 - 10 of 129
BioCentury | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

...College London ; Oxford Biomedica plc (LSE:OXB); University of Oxford ; University of Edinburgh ; Imperial Innovations...
BioCentury | Aug 10, 2018
Company News

Boehringer, U.K. groups partner for CF gene therapy

...to develop a gene therapy to treat cystic fibrosis. Partners include Oxford BioMedica plc (LSE:OXB), Imperial Innovations...
...Financial terms were undisclosed. Boehringer Ingelheim GmbH, Ingelheim, Germany Oxford BioMedica plc (LSE:OXB), Oxford, U.K. Imperial Innovations...
...Oxford, Oxford, U.K. University of Edinburgh, Edinburgh, U.K. Business: Pulmonary Michael von Emster Boehringer Ingelheim GmbH Imperial College London Imperial Innovations...
BioCentury | Jun 11, 2018
Company News

Management tracks: Arbutus, Cancer Research UK

...U.K.) hired Tony Hickson as CBO, effective in August. He is managing director at the Imperial Innovations...
BioCentury | Apr 30, 2018
Financial News

Andera leads Crescendo’s $70M series B

...a timeline. The company raised $28.6 million in a 2013 series A round led by Imperial Innovations...
BioCentury | Oct 26, 2017
Strategy

Capital call

...But there’s an interesting model seen with BTG plc , IP Group plc , and Imperial Innovations...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...2016 with £40 million ($57 million) by UCL, Cambridge University and Imperial College London ’s Imperial Innovations...
BioCentury | Mar 25, 2017
Finance

Respiratory redux

...an undisclosed sum. Pulmocide also has three investors in common with RespiVert: SV Life Sciences, Imperial Innovations...
BioCentury | Nov 11, 2016
Financial News

Enterprise Therapeutics completes venture financing

...£4 million ($5 million) in a venture round led by existing investors Epidarex Capital and Imperial Innovations...
BioCentury | Nov 11, 2016
Emerging Company Profile

Golden opportunity

...partners: None Number of employees: 14 Funds raised: £7 million ($8.6 million) Investors: Brandon Capital, Imperial Innovations...
BioCentury | Oct 3, 2016
Financial News

Artios completes venture financing

...2016-09-21 Type: Venture financing Raised: $33.2 million Investors: SV Life Sciences ; Merck Ventures B.V.; Imperial Innovations...
Items per page:
1 - 10 of 129